Kit for detecting homocysteine or metabolite thereof and method for detecting homocysteine or metabolite thereof

By providing a kit containing calibrators, sample release agents and internal standards, combined with C18 chromatography columns and specific mobile phases, the separation difficulties and storage problems in the detection of homocysteine ​​and its metabolites are solved, achieving high throughput and High sensitivity detection effect.

CN119000968APending Publication Date: 2024-11-22SUZHOU PANOMIX BIOTECH CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410791099.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-19
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art is difficult to detect various homocysteines and their metabolites at the same time, especially the separation of methylmalonic acid and succinic acid, and the sample processing flux is low, the kit storage time is short, and it cannot be used at non-ultra-low temperatures. Long-term preservation in the environment.

Method used

Provide a kit containing calibrator, sample release agent and internal standard, using a C18 chromatographic column and specific mobile phase combination to simplify sample processing, achieve high throughput and high sensitivity detection, and solve the problem of methylmalonic acid and succinic acid. Separation problem and long-term storage of reagents in non-ultra-low temperature environments.

Benefits of technology

It realizes high-throughput and high-sensitivity detection of a variety of homocysteines and their metabolites, solves the separation problem of methylmalonic acid and succinic acid, extends the storage time of the kit, and is suitable for clinical large-scale testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119000968A_ABST
    Figure CN119000968A_ABST
Patent Text Reader

Abstract

The invention provides a kit for detecting homocysteine or metabolites thereof and a method for detecting homocysteine or metabolites thereof. The kit comprises a calibrator and a sample releasing agent, the calibrator comprises a component 1, a component 2 and a component 3. The kit provided by the invention is used for detecting homocysteine or metabolites thereof, and high-flux and high-sensitivity detection of various homocysteine and metabolites thereof can be realized only through extremely simple and convenient sample treatment; the problem of separation of methylmalonic acid and succinic acid is solved, the problems that existing T3 chromatographic columns, AQ chromatographic columns, HILIC chromatographic columns and the like need high-water-phase separation of strong-polarity substances and the like are solved, the homocysteine metabolite can be stored for a long time in a non-ultralow-temperature environment, and the problems that a homocysteine metabolite kit is short in reagent storage time and the like are solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of in vitro diagnostic medical testing, and specifically relates to a kit for detecting homocysteine ​​or its metabolites and a method for detecting homocysteine ​​or its metabolites. Background Art

[0002] Homocysteine ​​(Hcy) is a thiol-containing non-protein amino acid. It is a metabolite of the essential amino acid methionine and a metabolic intermediate produced by the demethylation of methionine in the body. It has multiple functions such as regulating the cell cycle and maintaining cell homeostasis. Hcy metabolism contributes to the folate-dependent / independent remethylation to form methionine, as well as the transsulfurization pathway to form cysteine. Through the analysis of the Hcy metabolic pathway, it can be found that the increase of Hcy is related to multiple factors, including: ① 5-methyltetrahydrofolate (5-MTHF) deficiency: 5-MTHF, also known as active vitamin B9, is the substrate of Hcy remethylation reaction and the active metabolite of folic acid in the body, so folic acid supplementation is beneficial for reducing Hcy; ② Vitamin B6 and B12 are important coenzymes that play a catalytic role in the metabolism of Hcy, so vitamin B6 and B12 deficiency may be related to the increase of Hcy; ③ Betaine provides methyl groups for Hcy to convert it into methionine, so the decrease in betaine levels is also related to the increase of Hcy.

[0003] Studies have shown that in the diagnostic process of hyperHcyemia, the measurement of methylmalonic acid (MMA) and Hcy metabolites is more sensitive than the measurement of serum vitamin B12 levels alone for diagnosing hyperHcyemia caused by vitamin B12 deficiency. In some countries, methionine is one of the markers of the newborn screening program, and elevated methionine is used to evaluate CBS deficiency and methylation defects. In addition, studies have found that compared with Hcy, S-adenosylhomocysteine ​​(SAH), as a precursor of Hcy, may be a more sensitive indicator for predicting cardiovascular disease risk. In addition, reports have shown that plasma choline and betaine concentrations are both on the rise during pregnancy and are associated with increased plasma tHcy. The mechanisms include the consumption of choline and betaine in the liver caused by pregnancy, as well as pregnancy-induced Hcy production, which in turn induces endogenous synthesis of choline. Therefore, the detection of full-pathway metabolites and coenzymes of Hcy (vitamin B2, vitamin B6, vitamin B9, 5-methyltetrahydrofolate, homocysteine, S-adenosylhomocysteine, methylmalonic acid, vitamin B12, betaine, choline) has a high clinical reference value.

[0004] LC-MS / MS technology is the gold standard for detecting small molecules and is often used for the detection of vitamins, hormones and other substances. Since homocysteine ​​substitutes are endogenous substances with strong polarity and a lot of endogenous interference, methylmalonic acid is in negative ion mode in the mass spectrometer, and positive and negative ion switching is required when detecting it simultaneously with other substances, and methylmalonic acid needs to be completely separated from its isomer succinic acid in serum, all of which pose challenges to the detection method. Another challenge is that as a medical detection method, it requires higher sample processing and detection throughput.

[0005] Among the currently reported detection methods, such as CN113009033A and CN115754062A, both require nitrogen drying and re-dissolution steps when processing serum samples, which seriously restricts the sample processing throughput, and neither detects methylmalonic acid and vitamin B12, which are key indicators in the homocysteine ​​pathway.

[0006] In CN115436536A, protein precipitation was used to treat samples to detect 18 hyperhomocysteinemia-related markers including methylmalonic acid, but pyridoxal phosphate, the active ingredient in vitamin B6, was not detected. The pretreatment used protein precipitation, which effectively solved the throughput problem of sample processing. Since homocysteine ​​metabolites are all highly polar compounds, this method uses the traditional HILIC mode to detect the problem of poor retention of highly polar compounds in reversed-phase chromatographic columns, but the HILIC column requires a high concentration of salt solution to maintain the chromatographic peak shape, and the HILIC column requires a long period of equilibrium during use, the use conditions are relatively harsh, and the durability is also poor. Therefore, this method cannot be used for large-scale sample detection in clinical laboratories.

[0007] Therefore, how to provide a method that can simultaneously detect multiple homocysteine ​​and its metabolites, with accurate detection and good separation effect of methylmalonic acid and succinic acid has become an urgent problem to be solved. Summary of the invention

[0008] In view of the deficiencies of the prior art, the object of the present invention is to provide a kit for detecting homocysteine ​​or its metabolites and a method for detecting homocysteine ​​or its metabolites. The kit provided by the present invention is used for detecting homocysteine ​​or its metabolites, and only requires extremely simple sample processing to achieve high-throughput and high-sensitivity detection of a variety of homocysteine ​​and its metabolites, solves the separation problem of methylmalonic acid and succinic acid, and the current T3 chromatographic column, AQ chromatographic column, HILIC chromatographic column, etc. require a high aqueous phase to separate highly polar substances. It can be stored for a long time in a non-ultra-low temperature environment, solving the problem of short storage time of homocysteine ​​metabolite kit reagents.

[0009] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0010] In one aspect, the present invention provides a kit for detecting homocysteine ​​or its metabolites, the kit comprising a calibrator and a sample release agent.

[0011] The calibrator comprises component 1, component 2 and component 3.

[0012] The component 1 comprises human serum albumin and / or animal serum albumin.

[0013] The component 2 includes isoascorbic acid and / or citric acid.

[0014] The component 3 includes any one of riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline or methylmalonic acid, or a combination of at least two thereof.

[0015] The above-mentioned specific kit is used to detect homocysteine ​​or its metabolites. It only requires extremely simple sample processing to achieve high-throughput and high-sensitivity detection of various homocysteine ​​and its metabolites, and solves the separation problems of methylmalonic acid and succinic acid and the current T3 column, AQ column and HILIC column that require a high aqueous phase to separate highly polar substances. It can be stored for a long time in a non-ultra-low temperature environment, solving the problem of short storage time of homocysteine ​​metabolite kit reagents.

[0016] Preferably, the sample release agent comprises any one of trichloroacetic acid, metaphosphoric acid, sulfosalicylic acid or tri(2-carbonylethyl)phosphine hydrochloride (TECP) or a combination of at least two thereof, preferably a combination of metaphosphoric acid and tri(2-carbonylethyl)phosphine hydrochloride.

[0017] The above-mentioned specific sample releaser combination can effectively improve the sensitivity of methylmalonic acid detection.

[0018] The kit further comprises an internal standard, which comprises an internal standard of homocysteine ​​or its metabolite.

[0019] Preferably, the internal standard includes any one or a combination of at least two of riboflavin-13C4,15N2, pyridoxal phosphate-d3, pyridoxic acid-d3, folic acid-d4, 5-methyltetrahydrofolate-13C5, methionine-d3, S-adenosylhomocysteine-d4, homocysteine-d4, betaine-d9 base, choline-d9 or methylmalonic acid-d3.

[0020] Preferably, the kit further comprises a quality control product, and the composition of the quality control product is the same as that of the calibrator.

[0021] Preferably, the kit further comprises a mobile phase, and the mobile phase comprises methanol and water.

[0022] Preferably, the kit further comprises a mobile phase additive, wherein the mobile phase additive comprises formic acid and ammonium acetate.

[0023] Preferably, in the kit, each component exists in the form of a solution, wherein the mass fraction of the solution of component 1 is 0.1-5%, the mass fraction of the solution of component 2 is 0.1-2%, and in the sample release agent, the mass fraction of the solution of metaphosphoric acid is 3-7%, the concentration of the solution of TECP is 40-60mM, and the mass fraction of the solution of sulfosalicylic acid is 3-7%.

[0024] On the other hand, the present invention also provides a method for detecting homocysteine ​​or its metabolites, the detection method comprising the following steps:

[0025] The sample to be tested is treated with the kit as described above, and then subjected to LC-MS (liquid chromatography tandem mass spectrometry) detection, and the content of homocysteine ​​or its metabolites in the sample to be tested is calculated based on the detection results.

[0026] The homocysteine ​​or its metabolite includes any one or a combination of at least two of riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline or methylmalonic acid.

[0027] Preferably, the homocysteine ​​or its metabolites include riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline and methylmalonic acid.

[0028] Preferably, the specific steps of treating the sample to be tested using the kit as described above are:

[0029] The sample to be tested and the calibrator are mixed with the sample release agent respectively, and then centrifuged to obtain the supernatant.

[0030] Preferably, the specific step of treating the sample to be tested using the kit as described above further includes:

[0031] The sample to be tested and the standard are mixed with the internal standard and the sample release agent respectively, and then centrifuged to obtain the supernatant.

[0032] Preferably, the chromatographic column for LC-MS detection is a C18 chromatographic column.

[0033] When using HILIC columns in the prior art, a high concentration of ammonium salt is required in the mobile phase, and HILIC requires a longer equilibrium time and harsh operating conditions. Using a C18 column instead of a HILIC column can effectively solve the above problems, and can also effectively solve the problems of T3 columns, AQ columns, HILIC columns, etc. that require a high aqueous phase to separate highly polar substances.

[0034] Preferably, the mobile phase for LC-MS detection includes mobile phase A and mobile phase B, wherein mobile phase A is a methanol aqueous solution containing formic acid and ammonium acetate, and mobile phase B is methanol containing formic acid and ammonium acetate; in mobile phase A and mobile phase B, the mass fraction of formic acid is independently 0.05-2%, and the concentration of ammonium acetate is independently 0.5-10 mM.

[0035] Preferably, the column temperature of the LC-MS detection is 30-50°C, such as 30°C, 35°C, 40°C, 45°C or 50°C, but is not limited to the above-listed values. Other values ​​not listed within the above range are also applicable.

[0036] Preferably, the mobile phase flow rate of the LC-MS detection is 0.5-0.8 mL / min, such as 0.5 mL / min, 0.6 mL / min, 0.7 mL / min or 0.8 mL / min, but is not limited to the above-listed values, and other values ​​not listed within the above numerical range are also applicable.

[0037] Preferably, the elution procedure for the LC-MS detection is as follows:

[0038] From 0 to 0.3 min, the volume fraction of mobile phase A was 94-96%, and the rest was mobile phase B;

[0039] In the first 0.3-1.5 minutes, the volume fraction of mobile phase A changes from 94-96% to 8-12% at a constant rate, and the rest is mobile phase B;

[0040] From 1.5 to 3.5 min, the volume fraction of mobile phase A was 8-12%, and the rest was mobile phase B;

[0041] At 3.5-3.6 minutes, the volume fraction of mobile phase A changed at a constant rate from 8-12% to 94-96%, and the rest was mobile phase B.

[0042] Preferably, in the LC-MS detection, the quantitative ion pair of methylmalonic acid is 117-55.

[0043] Preferably, in the LC-MS detection, the collision voltage of methylmalonic acid is -15 to -55 V, for example -15 V, -20 V, -25 V, -35 V, -35 V, -40 V, -45 V, -50 V or -55 V, but is not limited to the above-listed values, and other values ​​not listed within the above numerical range are also applicable.

[0044] Preferably, in the LC-MS detection, the collision voltage of methylmalonic acid is -34 to -55V.

[0045] The above-mentioned specific quantitative ion pairs and collision voltage selection can effectively realize the mass spectrometry separation of succinic acid and methylmalonic acid, and will not be affected by the fluctuation of the detection system and excessive concentration, thereby better ensuring the stability and accuracy of the methylmalonic acid detection results.

[0046] Compared with the prior art, the present invention has the following beneficial effects:

[0047] The present invention provides a kit for detecting homocysteine ​​or its metabolites. The kit is used for detecting homocysteine ​​or its metabolites, and only extremely simple sample processing is required to achieve high-throughput and high-sensitivity detection of multiple homocysteine ​​and its metabolites, and solves the separation problem of methylmalonic acid and succinic acid and the problem that the current T3 chromatographic column, AQ chromatographic column and HILIC chromatographic column need a high aqueous phase to separate highly polar substances. The kit can be stored for a long time in a non-ultra-low temperature environment, and solves the problem of short storage time of reagents in the homocysteine ​​metabolite kit. BRIEF DESCRIPTION OF THE DRAWINGS

[0048] Figure 1 is the chromatogram of riboflavin in Example 1;

[0049] Figure 2 is the chromatogram of pyridoxal phosphate in Example 1;

[0050] Figure 3 is the chromatogram of pyridoxic acid in Example 1;

[0051] Figure 4 is the chromatogram of folic acid in Example 1;

[0052] Figure 5 is the chromatogram of 5-methyltetrahydrofolate in Example 1;

[0053] Figure 6 is the chromatogram of S-homocysteine ​​in Example 1;

[0054] Figure 7 is the chromatogram of homocysteine ​​in Example 1;

[0055] Figure 8 is the chromatogram of choline in Example 1;

[0056] Fig. 9 is the chromatogram of betaine in Example 1;

[0057] Fig.10 is the chromatogram of methionine in Example 1;

[0058] Fig.11 is the chromatogram of methylmalonic acid in Example 1;

[0059] Fig.12 This is the chromatogram of methylmalonic acid and succinic acid reference substances under ion pair 117-73 in the separation study of methylmalonic acid and succinic acid;

[0060] Fig.13 This is the chromatogram of serum sample at ion pair 117-73 in the separation study of methylmalonic acid and succinic acid;

[0061] Fig.14 This is the online mass spectrum of the methylmalonic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -15V;

[0062] Fig.15 This is the online mass spectrum of the succinic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -15V;

[0063] Fig.16 This is the online mass spectrum of the methylmalonic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -10V;

[0064] Fig.17 This is the online mass spectrum of the methylmalonic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -34V;

[0065] Fig.18 This is the online mass spectrum of the methylmalonic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -55V;

[0066] Fig.19 This is the online mass spectrum of the succinic acid reference substance in the separation study of methylmalonic acid and succinic acid, CE = -55V;

[0067] Fig. 20 This is the chromatogram of serum sample in the separation study of methylmalonic acid and succinic acid at ion pair 117-55, CE = -34V. DETAILED DESCRIPTION

[0068] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0069] Before describing various example embodiments and various example implementations of the present application in detail, in order to make various aspects of the present application clearer, the following terms are defined. Undefined or not particularly described terms and abbreviations should conform to the conventional meanings used in the art. Unless otherwise clearly stated in this article, all scientific and technological terms in this application have the same meaning as commonly understood by those of ordinary skill in the art. Unless otherwise clearly stated in this article, the present application relates to conventional techniques commonly used in the field of medical testing. It will be appreciated by those skilled in the art that names or terms with the same or similar meanings can be used interchangeably in this application.

[0070] Plasma proteins

[0071] As used herein, the term "plasma proteins", "blood proteins" or other similar expressions refer to proteins in human or animal plasma, and may include serum proteins (e.g., serum albumin), globulin, etc. Serum albumin may be, for example, bovine serum albumin (BSA).

[0072] Homocysteine ​​metabolites

[0073] As used herein, the term "homocysteine ​​metabolites" refers to small molecules on the homocysteine ​​metabolic pathway, such as methionine, S-adenosylhomocysteine, homocysteine, vitamin B2, vitamin B6, vitamin B9, 5-methyltetrahydrofolate, methylmalonic acid, betaine, and choline; wherein vitamin B2 is riboflavin, vitamin B6 is pyridoxal phosphate and pyridoxic acid, and vitamin B9 is folic acid.

[0074] Standard solutions and standard curves

[0075] As used herein, the terms "standard liquid / solution", "standard substance", "calibrator liquid / solution", "calibrator" or similar expressions all mean: a standard substance prepared using at least one of the components of a homocysteine ​​detection kit with a quantitative purity of >98% or a certified standard substance. After the standard substance is subjected to the following pretreatment and detection steps, a standard curve can be drawn or a standard regression function can be obtained with the concentration ratio (Concentration Ratio) of one or more analytes (e.g., biotin) to the corresponding internal standard as the horizontal coordinate and the mass spectrum peak area ratio (Area Ratio) of the one or more analytes to the corresponding internal standard as the vertical coordinate, which is used to calculate the actual content of the one or more analytes in the sample to be tested. Those skilled in the art can make various changes to the standard curve or regression function according to the actual application needs, such as other equivalent functions, lookup tables, etc.

[0076] Quality Control Products

[0077] As used herein, the terms "quality control", "quality control sample", "quality control solution" or other similar expressions may refer to one or more homocysteine ​​metabolite solutions / mixtures used to check the performance of an analytical instrument or analytical method. It will be understood by those skilled in the art that, for the homocysteine ​​metabolite to be tested, the composition of the quality control product / quality control solution may be the same as that of the standard, and the specific content and concentration of one or more water-soluble vitamins may be determined according to the relevant universal standards for in vitro diagnostic reagents.

[0078] Sample release agent

[0079] As used in this article, the term "sample releasing agent" or other similar expressions refers to a reagent that can release the homocysteine ​​metabolite to be detected in a human serum sample. The principle is to denature and precipitate the protein in human serum, thereby releasing the homocysteine ​​metabolite to be detected from the serum sample.

[0080] Positive ion mode

[0081] The terms "positive ion mode," "operating in positive mode," or "operating in positive ionization mode" refer to mass spectrometry methods in which positive ions are generated and detected.

[0082] Tandem mass spectrometry

[0083] Tandem mass spectrometry is a mass spectrometer in which mass spectrometers are connected in series, generally containing two or more mass analyzers, which are connected in series. The tandem mass spectrometer used in the present invention can be a triple quadrupole mass spectrometer, abbreviated as MS / MS or QQQ. The first MS refers to the quadrupole mass analyzer in front of the collision cell of the triple quadrupole, which is used to scan the parent ions of the substance, and the second MS refers to the quadrupole behind the collision cell, which is used to scan the fragment ions of the substance. The two quadrupoles are directly collision cells, which are used to fragment compounds and form fragment ions. In the first MS, ions representing one (and possibly more than one) chemical component are detected and recorded during the creation of the primary mass spectrum. The substance represented by the ion is subjected to a second MS or subsequent multiple MS, in which the substance of interest is fragmented so that the substance is decomposed into subcomponents, which will be detected and recorded as a secondary mass spectrum.

[0084] Chromatography

[0085] The term "chromatography" or "chromatography" refers to a physical separation method in which the components (i.e., chemical constituents) to be separated are distributed between two phases, one of which is stationary (stationary phase) and the other (mobile phase) moves in a defined direction. The mobile phase can be a gas ("gas chromatography", "GC") or a liquid ("liquid chromatography", "LC"). LC-MS / MS in the present invention refers to liquid chromatography-tandem mass spectrometry.

[0086] Example 1

[0087] This embodiment provides a kit for detecting homocysteine ​​and its metabolites and a method for detecting homocysteine ​​and its metabolites, which are specifically as follows:

[0088] 1. Preparation of the kit

[0089] 1.1 Preparation of blank matrix

[0090] 1) Measure 80 mL of 10× PBS and add it to 720 mL of purified water, mix well, and prepare 1× PBS solution;

[0091] 2) Weigh 0.8 g of isoascorbic acid and 0.8 g of bovine serum albumin powder, add them to 1× PBS bovine serum albumin solution, sonicate, dissolve, and set aside;

[0092] 1.2 Preparation of compound stock solutions

[0093] 1) Preparation of vitamin B2 stock solution: accurately weigh 5 mg of standard powder, add 2 mL of 20% methanol, then add 10 μL of ammonia water to dissolve, add 20 μL of formic acid to adjust the pH to weak acidity, add 20% methanol to make up to 5 mL, and prepare a vitamin B2 stock solution with a concentration of 1 mg / mL;

[0094] 2) Preparation of pyridoxalic acid stock solution: accurately weigh 5 mg of standard powder, add 10% methanol containing 0.1% isoascorbic acid, then add 20 μL of ammonia water to dissolve, then adjust the pH with 50 μL of formic acid, add 10% methanol to make the volume to 5 mL, and prepare a pyridoxalic acid stock solution with a concentration of 1 mg / mL;

[0095] 3) Preparation of pyridoxal phosphate stock solution: accurately weigh 5 mg of standard powder, add 10% methanol containing 0.1% isoascorbic acid, then add 20 μL of ammonia water to dissolve, then add 50 μL of formic acid to adjust the pH, add 10% methanol to make the volume to 5 mL, and prepare a pyridoxal phosphate stock solution with a concentration of 1 mg / mL;

[0096] 4) Preparation of 5-methyltetrahydrofolate stock solution: accurately weigh 5 mg of standard powder, add 20 μL of 20% methanol containing 0.1% DTT (dithiothreitol), then add about 40 μL of ammonia water to dissolve, then add 50 μL of formic acid to adjust the pH, and then add 20% methanol to make the volume to 5 mL to prepare a 5-methyltetrahydrofolate stock solution with a concentration of 1 mg / mL;

[0097] 5) Preparation of vitamin B9 stock solution: accurately weigh 5 mg of standard powder, add 20 μL of 20% methanol containing 0.1% DTT (dithiothreitol), then add about 40 μL of ammonia water to dissolve, then add 50 μL of formic acid to adjust the pH, and then add 20% methanol to make up to 5 mL to prepare a vitamin B9 stock solution with a concentration of 1 mg / mL;

[0098] 6) Preparation of methylmalonic acid stock solution: accurately weigh 5 mg of standard powder, add 20% methanol to make up to 5 mL, and prepare a methylmalonic acid stock solution with a concentration of 1 mg / mL;

[0099] 7) Preparation of methionine stock solution: accurately weigh 10 mg of standard powder, add 10% methanol to make up to 1 mL, and prepare a methionine stock solution with a concentration of 1 mg / mL;

[0100] 8) Preparation of homocysteine ​​stock solution: accurately weigh 10 mg of standard powder, add 0.5 mL of 10% methanol to volume, sonicate, then add 100 μL of 5 mM dilute hydrochloric acid solution, and finally add ultrapure water to make up to 1 mL to prepare a homocysteine ​​stock solution with a concentration of 1 mg / mL;

[0101] 9) Preparation of betaine stock solution: accurately weigh 10 mg of standard powder, add 0.5 mL of 10% methanol to volume, sonicate, add ultrapure water to make up to 1 mL, and prepare a betaine stock solution with a concentration of 1 mg / mL;

[0102] 10) Preparation of choline stock solution: accurately weigh 10 mg of standard powder, add 0.5 mL of 10% methanol to volume, sonicate, add ultrapure water to make up to 1 mL, and prepare a choline stock solution with a concentration of 1 mg / mL;

[0103] 11) Preparation of S-adenosylhomocysteine ​​stock solution: accurately weigh 5 mg of standard powder, add 5 mL of 10% methanol to volume, sonicate, add ultrapure water to make up to 5 mL, and prepare a S-adenosylhomocysteine ​​stock solution with a concentration of 1 mg / mL;

[0104] 3.3 Preparation of blank matrix

[0105] Weigh bovine serum albumin, isoascorbic acid and citric acid, place in a reagent bottle, add ultrapure water to prepare a blank matrix (containing 1% BSA albumin solution, 0.1% isoascorbic acid and 0.1% citric acid).

[0106] 3.4 Preparation of secondary stock solutions of homocysteine ​​and its metabolites

[0107] Take appropriate amounts of vitamin B2 stock solution, pyridoxic acid stock solution, vitamin B9 stock solution and 5-methyltetrahydrofolate stock solution and place them in reagent bottles respectively, dilute them 10 times with 20% methanol to make vitamin B2 secondary stock solution, pyridoxic acid secondary stock solution, vitamin B9 secondary stock solution and 5-methyltetrahydrofolate secondary stock solution (all with a concentration of 100 μg / mL).

[0108] 3.5 Preparation of Calibrator C5

[0109] Take different volumes of the stock solution / secondary stock solution of each compound and add them to the blank matrix, mix well, and prepare the calibrator C5 for use.

[0110]

[0111] 1.6 Preparation of Calibrators C1 to C4 and Quality Controls

[0112] C5 was diluted with blank matrix to prepare calibration products C1, C2, C3, C4 and quality control products QC1 and QC2. The concentrations of all calibration products and quality control products are as follows:

[0113]

[0114]

[0115] 1.7 Preparation of internal standard stock solution

[0116] Add 10% methanol to the powders of standard products such as vitamin B2-13C4-15N2, pyridoxal-d3, 5-pyridoxal phosphate-d3, 5-methyltetrahydrofolate-13C5, folic acid-d4, methylmalonic acid-d3, choline-d9, S-adenosylhomocysteine-d4 to prepare 1 mg / mL stock solutions; prepare methionine-d3, homocysteine-d8, and betaine-d9 to prepare 10 mg / mL stock solutions.

[0117] 1.8 Preparation of internal standard working solution

[0118] Pipette different volumes of internal standard stock solution into the blank matrix and mix well. The concentrations of each internal standard compound are shown in the following table. Store in a dark environment at 2°C to 8°C for later use.

[0119]

[0120] 1.9 Preparation of sample release agent

[0121] Weigh 100 g of metaphosphoric acid solid particles and 28 g of tri(2-carbonylethyl)phosphine hydrochloride (TCEP), add 2 L of water, dissolve them by ultrasonication, and dispense 30 mL each into 60 mL wide-mouth reagent bottles to obtain the product.

[0122] 1.10 Preparation of mobile phase

[0123] Preparation of mobile phase A: Mix 490 mL of deionized water with 5 mL of LC-MS grade methanol.

[0124] Preparation of mobile phase B: Directly dispense methanol into 500 mL volumes.

[0125] 1.11 Preparation of mobile phase additives

[0126] Take 240 mL of purified water, add 240 mL of formic acid and 35 g of ammonium acetate to prepare 480 mL of mobile phase additive.

[0127] 1.12 Freeze-drying of calibrators, quality controls and internal standards

[0128] The calibrators (C1-C4) and quality control products (QC1, QC2) were dispensed into 2.5 mL brown vials at 0.5 mL each, and the internal standard working solution was dispensed into 2.5 mL brown vials at 1 mL each. The vials were half-stoppered and placed in a freeze dryer for freeze drying. After freeze drying, the stoppers were pressed and the vials were taken out after the pressure was balanced.

[0129] The calibrators C1 to C5, quality control products QC1 and QC2, internal standards and sample release agents, mobile phases and mobile phase additives obtained after freeze-drying are assembled together in the outer packaging box of the kit to obtain a finished kit. The calibrators, quality control products, internal standards and sample release agents in the finished kit are stored at -20°C in the dark, and the mobile phase and mobile phase additives can be stored at room temperature.

[0130] 2. Use of the Kit

[0131] 2.1 Reconstitution

[0132] Take the kit prepared in 1, accurately pipette 0.5 mL of ultrapure water into each bottle of calibrator and quality control product (recorded as calibrator solution and quality control solution), accurately pipette 2 mL of ultrapure water into the internal standard bottle, mix for 1 min until the lyophilized powder is completely dissolved (recorded as internal standard solution), and set aside.

[0133] 2.2 Rewarming

[0134] Place the calibration solution, quality control solution, internal standard solution, sample to be tested, and sample release agent at room temperature (10°C-30°C) and allow to return to room temperature.

[0135] 2.3 Sample pretreatment

[0136] Take 100 μL of calibration solution, quality control solution, and sample to be tested in 1.5 mL EP tubes respectively, add 20 μL of internal standard solution, oscillate at 800 rpm for 10 min at 20 °C, add 100 μL of sample release agent, vortex mix, and centrifuge at 13000 rpm and 4 °C for 5 min; take 100 μL of supernatant in a 96-well plate and detect on the machine.

[0137] 3. Instrument conditions

[0138] 3.1 Liquid phase conditions

[0139] 1) Mobile phase A1: Add 1 mL of mobile phase additive to mobile phase A and mix well.

[0140] 2) Mobile phase B1: Add 1 mL of mobile phase additive to mobile phase B and mix well.

[0141] 3) Needle washing solution: prepare 500 mL of 50% methanol as needle washing solution.

[0142] 4) Chromatographic column: ZORBAX C18 column.

[0143] 5) Column temperature: 50°C.

[0144] 6) Injection volume: 10 μL.

[0145] 7) Automatic sampler temperature: 10°C.

[0146] 8) Mobile phase gradient:

[0147]

[0148] 3.2 Mass spectrometry ion source parameters

[0149]

[0150]

[0151] 3.3 Compound MRM parameters

[0152] 1) MRM parameters in positive ion mode

[0153]

[0154]

[0155] * indicates quantitation ion pair.

[0156] 2) MRM parameters in negative ion mode

[0157]

[0158] * indicates quantitation ion pair.

[0159] 4. Test kit performance verification

[0160] In order to verify the reliability of the results of the method of the present invention in detecting plasma or blood cell samples, a methodological investigation experiment (including quantitative lower limit, linearity, accuracy, precision, stability, etc.) was designed to verify the reliability of the detection method.

[0161] 1) Linear

[0162] After pretreatment, the calibrators were tested on the machine, and the detection concentrations of the calibrators C1 to C5 and the target concentrations were fitted with software to make a regression curve, and the linear correlation coefficient (r) was found to be ≥0.9900. The data are as follows:

[0163] Components Regression curve r Riboflavin y=0.12386x-0.00235 0.99976 Pyridoxal phosphate y=0.00166x+0.00678 0.99974 Pyridoxalic acid y=0.39052x+0.05309 0.99979 Folic acid y=0.01377x+0.00527 0.99915 5-Methyltetrahydrofolate y=0.00409x+0.00111 0.99974 Methionine y=3.35848E-4x+0.01200 0.99965 S-adenosylhomocysteine y=0.02100x+0.00566 0.99747 Homocysteine y=4.80766E-5x+0.00183 0.99976 Betaine y=0.00536x-9.83410E-4 0.99843 choline y=6.30123E-5x+3.19060E-5 0.99893 Methylmalonic acid y=0.00356x+0.01951 0.99986

[0164] The experimental results showed that the linear equation correlation coefficient of 11 homologous metabolites was >0.99, indicating that the detection method had a good linear relationship within the concentration range of C1 to C5.

[0165] 2) Lower limit of quantification

[0166] Referring to the sample processing method in 4.3, prepare LLOQ samples with the same concentration as calibrator C1 using blank matrix, test them in the same analytical batch, repeat the measurement 10 times, and calculate the mean value and coefficient of variation (CV).

[0167] The LLOQ sample was repeated 10 times, meeting the accuracy bias ≤±20%, CV ≤15%, and the data are as follows:

[0168] test Hc VB2 VB6-PA VB6-PLP VB9-FA 5-MTHF MMA Bet Cho Met SAH 1 671.09 0.6 0.41 5.77 1.14 0.81 17.21 79.55 38.44 384.88 2.49 2 665.95 0.63 0.47 6.05 1.32 0.88 19.65 83.53 40.16 370.2 2.85 3 636.23 0.46 0.56 4.3 1.02 0.91 15.63 79.58 34.87 380.27 2.63 4 647.13 0.48 0.45 5.05 1.03 1.01 16.09 81.46 35.56 369.92 2.58 5 661.24 0.44 0.4 4.58 0.92 1.14 22.3 78.36 40.04 385.95 2.97 6 687.69 0.6 0.45 4.42 1.06 1.18 21.91 78.62 38.24 383.94 3.01 7 643.04 0.58 0.38 4.74 1.15 1.01 22.24 81.7 38.86 373.88 2.96 8 650.06 0.61 0.42 5.13 1.17 0.77 22.8 81.69 42.65 388.74 2.95 9 657.27 0.44 0.49 6.15 0.92 0.96 18.62 78.82 37.64 382.83 2.78 10 652.04 0.49 0.46 5.23 1.29 1.15 19 79.82 39.37 380.05 2.86 Mean 657.17 0.53 0.45 5.14 1.10 0.98 19.55 80.31 38.58 380.07 2.94 Target value 700 0.5 0.5 5 1 1 20 80 40 400 3 Bias(%) -6.12 6.60 -10.20 2.84 10.20 -1.80 -2.27 0.39 -3.54 -4.98 -6.40 CV(%) 2.29 14.51 11.52 12.90 12.51 14.58 13.74 2.11 5.85 1.74 6.51

[0169] The test results showed that at the lower limit of qualitative analysis (LLOQ) concentration, the mean deviation of the test results was <±15%, and the precision CV was <15%, which met the acceptance criteria. The quantitative limit concentration of this method can achieve accurate detection.

[0170] 3) Accuracy

[0171] Accuracy verification uses two methods

[0172] (1) Hcy was tested by a certified reference material (homocysteine ​​frozen human serum national standard, batch number: 360047-202001, level II), meeting the accuracy bias ≤ ±15%;

[0173] (2) Other indicators were examined by spiked recovery rate, that is, homocysteine ​​and metabolite standard solutions were added to normal human serum, and spiked samples with low and high concentrations were prepared. Three samples of each concentration were prepared in parallel and tested in the same analytical batch. The average value was taken and the recovery rate was calculated according to the following formula: Recovery rate = average measured concentration / theoretical concentration × 100%.

[0174] Acceptance criteria: Recovery rate is within the range of 85% to 115%. The data are as follows:

[0175]

[0176]

[0177]

[0178]

[0179]

[0180]

[0181]

[0182]

[0183]

[0184]

[0185]

[0186]

[0187]

[0188]

[0189] The accuracy test results showed that the relative bias of HCY detection of reference substances at two concentration levels was less than ±15%, and the recovery rates of other indicators were all within the range of 85% to 115%. The results showed that the detection method had good accuracy and met the requirements of quantitative analysis.

[0190] 4) Precision

[0191] Referring to the sample processing method in Example 4.3, low and high concentrations of homocysteine ​​and metabolite standard solutions were added to normal human serum to prepare two concentrations of QC samples. Ten samples were tested at each concentration and three batches were analyzed repeatedly (one analysis batch per day). The QC samples were tested 10 times for a total of three days, and the CV values ​​of 30 data were calculated to meet CV≤15%. The data are as follows:

[0192]

[0193]

[0194]

[0195]

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207] The precision verification results showed that the precision CV was less than 15%, indicating that the precision of this method met the quantitative detection requirements.

[0208] 5) Room temperature stability

[0209] The test kit stored at -20℃ and the test kit placed at room temperature for 10 hours were opened at the same time and tested at the same time. For serum samples, the test kit placed at -20℃ is 0 hours, and the statistical method for stability at room temperature for 10 hours is:

[0210] Relative bias (Bias%) = (detection value at 10 h - detection value at 0 h) / detection value at 0 h × 100%.

[0211] A relative bias (Bias%) ≤ ±15% indicates good stability.

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224] The experimental results showed that the relative bias of the plasma samples tested after 10 hours at room temperature was less than ±15% compared with the test results at 0 hours, indicating that the kit has good stability at room temperature and can meet the requirements of use.

[0225] 5Real sample testing

[0226] The above method was used to detect 11 types of homocysteine ​​and its metabolites in serum samples. The test results are as follows: Figure 1-11 The specific results are as follows:

[0227] Serial number Compound Name Detection concentration (ng / mL) 1 Riboflavin 8.39 2 Pyridoxal phosphate 14.7 3 Pyridoxalic acid 2.78 4 Folic acid 1.67 5 5-Methyltetrahydrofolate 6.06 6 S-adenosylhomocysteine 12.84 7 Methionine 5282.79 8 Homocysteine 1653.56 9 Betaine 6864.72 10 choline 5013.31 11 Methylmalonic acid 9.61

[0228] Study on the Separation of Methylmalonic Acid and Succinic Acid

[0229] Succinic acid, also known as butyric acid, is an isomer of methylmalonic acid. It has a similar structure to methylmalonic acid and has similar characteristics under LC-MS detection conditions.

[0230] In the detection of homocysteine ​​and its metabolites, methylmalonic acid in the biological sample to be tested has obvious interference from succinic acid, so quantitative detection of methylmalonic acid cannot be performed. In order to separate methylmalonic acid and succinic acid, we prepared methylmalonic acid and succinic acid reference solutions of the same concentration (accurately weigh 5 mg of methylmalonic acid and succinic acid powder, add 20% methanol to 5 mL, prepare methylmalonic acid and succinic acid stock solutions with a concentration of 1 mg / mL, and then dilute the mixed stock solution to 100 ng / mL with 50% methanol solution) and enter the LC-MS system for detection (the following detection, unless otherwise specified, the detection conditions are consistent with Example 1), and the baseline separation of methylmalonic acid and succinic acid is achieved, as shown in Figure 1. Fig.12 shown.

[0231] However, when testing serum samples, it was found that the content of succinic acid in serum was significantly higher than that of methylmalonic acid ( Fig.13 ). Therefore, it can be seen that the response of succinic acid in serum samples is too high (the concentration of succinic acid is much higher than that of methylmalonic acid). Under the optimal LC conditions, it will still affect the detection of methylmalonic acid, making its quantitative results inaccurate.

[0232] Methylmalonic acid and succinic acid are isomers of functional group position isomers. Theoretically, their mass spectrometry fragmentation rules are similar and they contain the same fragment ions. However, under the conditions of the present invention, methylmalonic acid has a fragment ion of m / z=55 under the condition of CE (collision voltage) of -15V, while succinic acid does not form this fragment ion. Figure 14-15 shown.

[0233] Methylmalonic acid and succinic acid reference substances were further tested under different CE conditions, such as Figure 16-19 As shown. From the results of the above figures, it can be seen that when CE = -10V, methylmalonic acid has no fragment ion of m / z = 55, and as the collision energy increases, methylmalonic acid has a fragment ion of m / z = 55 and the intensity of the ion tends to increase, while succinic acid does not form a fragment ion of m / z = 55 under high and low collision energies. Therefore, the present invention selects 117-55 as the quantitative ion pair of methylsuccinic acid, and the CE energy is set to -15V and above, preferably -34V and above, and more preferably -34V to 55V. Under CE = -34V, the serum sample is tested, and the chromatogram obtained is as follows Fig. 20 As shown in the figure, there is no interference peak of succinic acid. In this way, the mass spectrometry separation of succinic acid and methylmalonic acid is achieved. Unlike LC condition separation, it is not affected by the fluctuation of the detection system and the excessive concentration, which better ensures the stability and accuracy of the methylmalonic acid detection results.

[0234] Selection of sample release agent

[0235] In order to improve the sensitivity of the detection method and to detect 11 compounds simultaneously, the present invention investigated different sample release agents.

[0236] Sample release agent ①: Weigh 100g of metaphosphoric acid solid particles and 28g of tri(2-carbonylethyl)phosphine hydrochloride (TCEP), add 2L of water, dissolve by ultrasonication, and dispense 30mL each into 60mL wide-mouth reagent bottles to obtain;

[0237] Sample release agent ②: Weigh 100g of trichloroacetic acid solid particles, add 1L of water, dissolve it by ultrasonic, and dispense 30mL each into 60mL wide-mouth reagent bottles;

[0238] Sample release agent ③: methanol;

[0239] Sample release agent④: acetonitrile;

[0240] Sample release agent ⑤: Measure 29.5mL of water into a 60mL wide-mouth reagent bottle, add 500μL of hydrochloric acid and mix well;

[0241] Sample release agent ⑥: Weigh 128 g of metaphosphoric acid solid particles, add 2 L of water, dissolve it by ultrasonic, and dispense 30 mL each into 60 mL wide-mouth reagent bottles.

[0242] Other conditions were the same, and 11 compounds were tested on serum samples. The test results are as follows:

[0243]

[0244] It can be seen from the results in the above table that different sample releasers give different test results. Considering the simultaneous detection of 11 compounds, especially pyridoxal phosphate, folic acid and methylmalonic acid with low responses, the preferred combination of metaphosphoric acid and TCEP of the present invention can achieve more effective detection.

[0245] The applicant declares that the present invention illustrates the kit for detecting homocysteine ​​or its metabolites and the method for detecting homocysteine ​​or its metabolites through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

[0246] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.

[0247] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.

Claims

1. A kit for detecting homocysteine ​​or its metabolites, characterized in that: The kit includes a calibrator and a sample release agent; The calibrator comprises component 1, component 2 and component 3; The component 1 comprises human serum albumin and / or animal serum albumin; The component 2 comprises isoascorbic acid and / or citric acid; The component 3 includes any one of riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline or methylmalonic acid, or a combination of at least two thereof.

2. The kit according to claim 1, characterized in that The sample release agent includes any one of trichloroacetic acid, metaphosphoric acid, sulfosalicylic acid or tri(2-carbonylethyl)phosphine hydrochloride or a combination of at least two thereof, preferably a combination of metaphosphoric acid and tri(2-carbonylethyl)phosphine hydrochloride.

3. The kit according to claim 1 or 2, characterized in that The kit further comprises an internal standard, wherein the internal standard comprises an internal standard of homocysteine ​​or a metabolite thereof; Preferably, the internal standard includes any one or a combination of at least two of riboflavin-13C4,15N2, pyridoxal phosphate-d3, pyridoxic acid-d3, folic acid-d4, 5-methyltetrahydrofolate-13C5, methionine-d3, S-adenosylhomocysteine-d4, homocysteine-d4, betaine-d9 base, choline-d9 or methylmalonic acid-d3.

4. The kit according to any one of claims 1 to 3, characterized in that The kit also includes a quality control product, and the composition of the quality control product is the same as that of the calibration product.

5. The kit according to any one of claims 1 to 4, characterized in that The kit further comprises a mobile phase comprising methanol and water.

6. The kit according to claim 5, characterized in that The kit also includes a mobile phase additive comprising formic acid and ammonium acetate.

7. A method for detecting homocysteine ​​or its metabolites, characterized in that: The detection method comprises the following steps: The sample to be tested is treated with the kit according to any one of claims 1 to 6, followed by LC-MS detection, and the content of homocysteine ​​or its metabolites in the sample to be tested is calculated according to the detection result; The homocysteine ​​or its metabolite includes any one or a combination of at least two of riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline or methylmalonic acid.

8. The detection method according to claim 7, characterized in that: The homocysteine ​​or its metabolites include riboflavin, pyridoxal phosphate, pyridoxic acid, folic acid, 5-methyltetrahydrofolate, methionine, S-adenosylhomocysteine, homocysteine, betaine, choline and methylmalonic acid; Preferably, the specific steps of treating the sample to be tested using the kit according to any one of claims 1 to 6 are: The sample to be tested and the calibrator are mixed with the sample release agent respectively, and then centrifuged to obtain the supernatant; Preferably, the specific step of treating the sample to be tested using the kit according to any one of claims 1 to 6 further comprises: The sample to be tested and the standard are mixed with the internal standard and the sample release agent respectively, and then centrifuged to obtain the supernatant.

9. The detection method according to claim 7 or 8, characterized in that: The chromatographic column detected by the LC-MS is a C18 chromatographic column; Preferably, the mobile phase for LC-MS detection includes mobile phase A and mobile phase B, wherein mobile phase A is a methanol aqueous solution containing formic acid and ammonium acetate, and mobile phase B is methanol containing formic acid and ammonium acetate; Preferably, the column temperature of the LC-MS detection is 30-50°C; Preferably, the mobile phase flow rate of the LC-MS detection is 0.5-0.8 mL / min; Preferably, the elution procedure for the LC-MS detection is as follows: From 0 to 0.3 min, the volume fraction of mobile phase A was 94-96%, and the rest was mobile phase B; In the first 0.3-1.5 minutes, the volume fraction of mobile phase A changes from 94-96% to 8-12% at a constant rate, and the rest is mobile phase B; From 1.5 to 3.5 min, the volume fraction of mobile phase A was 8-12%, and the rest was mobile phase B; At 3.5-3.6 minutes, the volume fraction of mobile phase A changed at a constant rate from 8-12% to 94-96%, and the rest was mobile phase B.

10. The detection method according to any one of claims 7 to 9, characterized in that: In the LC-MS detection, the quantitative ion pair of methylmalonic acid is 117-55; Preferably, in the LC-MS detection, the collision voltage of methylmalonic acid is -15 to -55 V; Preferably, in the LC-MS detection, the collision voltage of methylmalonic acid is -34 to -55V.

Citation Information

Cited By

  • Metabolic spectrum detection kit based on three differential metabolites and application thereof

    CN121978245A